Genetics | Oncogenetics
The test that identifies predisposition to breast and ovarian cancer
Genetics | Oncogenetics
The test that identifies predisposition to breast and ovarian cancer
Genetics | Oncogenetics
The test that identifies predisposition to breast and ovarian cancer
5-7% of breast cancers and 7-10% of ovarian cancers are hereditary and often associated with mutations in the BRCA1 and BRCA2 genes (Source: AIRC, the Italian Association for Cancer Research)
Women with BRCA1 or BRCA2 mutations have up to an 87% risk of developing breast cancer and up to a 40% risk of developing ovarian cancer1,2,3,4
Identifying individuals at risk makes it possible to:
- Implement preventive strategies, also for family members
- Initiate targeted therapies in cases of already diagnosed cancer
Book your BRCA1 e BRCA2 genetic test in 3 simple steps, or complete the contact form at the bottom of the page to request more information:
2. Provide a blood sample (home collection available!)
Receive your report online
The test has identified mutations in the BRCA1/BRCA2 genes associated with a high risk of developing breast, ovarian, or other cancers. Not all individuals with BRCA1/2 pathogenic mutations will develop cancer, but their risk is higher than that of the general population.
The test may sometimes reveal mutations whose clinical significance is uncertain or unknown — meaning it is not currently possible to determine whether they are benign variants of the gene or ones that may increase cancer risk.
The test did not identify any BRCA1/2 mutations associated with an increased risk of breast or other cancers. These individuals have a risk level comparable to that of the general population. However, a negative result does not exclude the presence of other risk factors for breast and ovarian cancer that are not detectable by the BRCA1/2 test.
The test is performed at the Pavia operational site, which implements a quality management system in accordance with ISO 9001:2015 and SIGUCert standards